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Abstract
Background: Androgen signaling plays a critical role in the development of prostate cancer and its progression. 
However, androgen-independent prostate cancer cells emerge after hormone ablation therapy, resulting in significant 
clinical problems. We have previously demonstrated that the HOXB13 homeodomain protein functions as a prostate 
cancer cell growth suppressor by inhibiting androgen-mediated signals. However, the role of the HOXB13 in androgen-
independent growth of prostate cancer cells remains unexplained.
Results: In this report, we first demonstrated that HOXB13 was highly overexpressed in hormone-refractory tumors 
compared to tumors without prostate-specific antigen after initial treatment. Functionally, in an androgen-free 
environment minimal induction of HOXB13 in LNCaP prostate cancer cells, to the level of the normal prostate, 
markedly promoted cell proliferation while suppression inhibited cell proliferation. The HOXB13-mediated cell growth 
promotion in the absence of androgen, appears to be mainly accomplished through the activation of RB-E2F signaling 
by inhibiting the expression of the p21waf tumor suppressor. Indeed, forced expression of HOXB13 dramatically 
decreased expression of p21waf; this inhibition largely affected HOXB13-mediated promotion of E2F signaling.
Conclusions: Taken together, the results of this study demonstrated the presence of a novel pathway that helps 
understand androgen-independent survival of prostate cancer cells. These findings suggest that upregulation of 
HOXB13 is associated with an additive growth advantage of prostate cancer cells in the absence of or low androgen 
concentrations, by the regulation of p21-mediated E2F signaling.
Background
Hox homeobox genes contain highly homologous home-
odomains and are considered transcription factors that
regulate axial regional specification during embryonic
development. Due to temporal and spatial colineality,
Hox  genes are expressed in a tissue-specific and fre-
quently stage-related fashion. The Hox-13 paralog is
especially important to the development of accessory sex-
ual organs, including the prostate gland [1-3]. Hoxb13 has
been shown to have limited expression at the caudal
extent of the spinal cord, tail bud and urogenital sinus in
an androgen-independent manner [4,5]. The expression
of HOXB13 is restricted but abundant in the adult human
prostate, representing almost one out of 2,000 transcripts
[6]. However, the role of HOXB13 during the adult stage
is mostly unknown. Mice homozygous for Hoxb13 loss-
of-function mutations have shown overgrowth in all
major structures derived from the tail bud [7] and malfor-
mation of the ducts of the ventral prostate, including
complete loss of secretory proteins [8]. Hoxb13 mutant
mice do not develop a prominent phenotypical change
but do have a swollen prostate in old mice, probably due
to the functional redundancy of other Hox-13 molecules.
Prostate cancer (PCa) is the most commonly diagnosed
cancer in North American men; a significant number of
p a t i e n t s  m a n i f e s t  a n d r o g e n  r e s i s t a n t  PC a,  l e a d i n g  t o  a
fatal disease. Androgen receptor (AR) activity is essential
to the growth and progression of PCa at all phases of the
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disease [9,10]. Therefore, androgen ablation therapy is
the frontline treatment for metastatic PCa; however, the
clinical response is transient, resulting in the recurrence
of tumors. These androgen-independent (AI) tumors
paradoxically depend on the AR [11,12], suggesting that
AR-mediated signaling is required for the growth of can-
cer cells, even when absent or present only in low concen-
trations. However, the regulation of AR target genes
under androgen-deprived conditions is not fully under-
stood. There is evidence to support a link between the
role of HOXB13 and the malignant progression of PCa.
The highly prostate-specific HOXB13 is involved in the
formation and maintenance of this hormone-dependent
organ [5,6,13,14]. In our previous studies, HOXB13
expression was correlated with the AR in both cultured
PCa cells and PCa xenograft models. All PCa cell lines
retaining the AR expressed moderate to high levels of
HOXB13 whereas AR-negative cells had low to undetect-
able amounts of HOXB13. However, the expression of
HOXB13 and AR was not mutually regulated [5,15].
There is also close functional and mechanistic communi-
cations between HOXB13 and AR signaling. HOXB13
suppresses androgen-stimulated AR activity by physical
interaction with the AR and subsequently inhibits the
growth-regulating function of AR [15]. Due to the multi-
focal nature of PCa, however, the pattern of expression of
HOXB13, during prostate tumorigenesis, has not been
well defined [15,16]. These results suggest that the bal-
ance between the HOXB13 and the AR (and/or hormone
response) may be important in the development and pro-
gression of PCa cells. In this study, we investigated the
pattern of expression of HOXB13 in androgen-dependent
(AD) and AI tumors and the functional and mechanistic
role of HOXB13 in hormone-refractory PCa cells.
Results
Anti-HOXB13 antibodies
To study the tissue distribution and expression pattern of
HOXB13 protein in PCas, HOXB13-specific antibodies
are critical tool. To date, there are no anti-HOXB13 anti-
bodies suitable for immunohistochemistry that can be
purchased in the commercial market. Therefore, anti-
HOXB13 antibodies were developed and their specificity
to HOXB13 was tested by Western blot analysis using
various PCa cell lines. As shown in Figure 1A, anti-
HOXB13 antibodies had a band at 35kDa, which was
highly expressed in the LNCaP, C42, and MDAPCa2b
cells, with only minor to no expression in the PC3,
DU145, P69, and CWR22RV cells. These results were
consistent with the expression pattern of HOXB13 RNA
as previously demonstrated [15]. These anti-HOXB13
antibodies did not react with recombinant homologous
HOXA13 or HOXD13 in transfection experiments (data
not shown). However, the antibodies nonspecifically
reacted to protein around 50kDa. To confirm that the
antibodies could be used to localize HOXB13 in tumor
cells, immunocytochemistry was performed in both
HOXB13 positive and negative cells (Figure 1B).
HOXB13 was detected in the nuclear compartment of
HOXB13-positive LNCaP and MDAPCa2b cells, but not
in the HOXB13-negative PC3 and DU145 cells; these
findings suggested that antibodies did not react to the
native form of the 50 kDa protein observed in the West-
ern blot. Next, to evaluate the tissue expression of
HOXB13 in PCas, immunohistochemistry was per-
formed on formalin-fixed and paraffin-embedded PCas
(Figure 1C). Similar to the results of prior mouse studies
[4,5], moderate expression of HOXB13 was observed in
benign prostate luminal epithelium, which was confined
to the nuclear compartment (arrows in upper row). In
localized PCas, some ductal epithelial cells highly
expressed HOXB13 (arrows in middle row) while some
ducts did not (lower row), probably due to the multifocal
and heterogeneous nature of PCa.
HOXB13 was overexpressed in androgen-refractory 
prostate cancer
The expression of HOXB13 was investigated in tumor
specimens from failed androgen ablation therapy and
compared to tumors without PSA recurrence. Fifty six
clinical samples of hormone-dependent (n = 44) and hor-
mone-refractory (n = 12) PCas were successfully stained.
Among AD tumors, 31 (70%) showed negative or weak
staining (score 0-1) and only 13 (30%) had moderate or
strong staining (score 2-3) for HOXB13. In Figure 2A,
AD1 represents no HOXB13 expression while AD2-3
r e p r e s e n t s  m o d e r a t e  t o  h i g h  e x p r e s s i o n  o f  H O X B 1 3 .
Although there were some difficulties in the precise scor-
ing of the HOXB13 expression due to the heterogeneous
population of PCa, expression of HOXB13 in the AD
tumors were predominantly low. Of note was that the AD
tumors with high Gleason scores tended to have high
expression of HOXB13 (data not shown). For the hor-
mone-refractory tumors, however, 10 (83%) samples
showed moderate to strong expression while only 2 (17%)
were negative or weak. At least 50% of tumor cells over-
expressed HOXB13 in the 10 samples. All 12 AI samples
are shown in Figure 2A AI 1-12. Figure 2B shows the dis-
tribution of the HOXB13 expression scores in the andro-
gen independent and androgen dependent tumors.
Overall, hormone-refractory tumors showed significantly
stronger expression of HOXB13 than androgen depen-
dent tumors (Pearson's = 11.2707, p  = 0.0008) (Figure
2C), suggesting that HOXB13 expression is somehow
altered, or that high HOXB13 expressing cells are
selected during androgen-independent progression of
PCa.Kim et al. Molecular Cancer 2010, 9:124
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Figure 1 Validation of HOXB13-specific antibodies in prostate cancers: Expression of HOXB13 in various PCa cells by Western blot analysis (A) 
and immunocytochemistry (B). While LNCaP and MDA PCa 2b cells were HOXB13-retained cells, PC3 and DU145 cells were HOXB13-deficient cells. 
HOXB13 was immunostained in prostates with normal or tumor tissue with routine hematoxyline-eosin staining. Arrows indicate HOXB13 localized 
to the nucleus of luminal epithelial cells or cancer cells.
$ % $ %
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Figure 2 Expression of HOXB13 in hormone-refractory prostate cancers: A, HOXB13 was immunostained in both androgen-dependent (AD) and 
androgen-independent (AI) tumors. AI tumors were acquired through transurethral resection of the prostate. High-powered pictures are shown in 
inlets of some selected figures. B, Dot plot demonstration of HOXB13 scores from each of the AD and AI tumors. Expression of HOXB13 in each tumor 
was scored (0, absent; 1, weak; 2, intermediate; and 3, strong). C, scores of HOXB13 are shown in the bar graph. The p value was determined by Pear-
son's chi square statistics with a value of 11.2707. *. p = 0.0008.
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Alteration of HOXB13 expression in LNCaP prostate cancer 
cells
In our previous studies [15,17], we found that constitutive
expression of HOXB13 drove PCa cells to cell death. To
avoid unwanted xenotoxic effects caused by HOXB13, we
have developed HOXB13-inducible cell lines using the
Tet-On system (BD Biosciences). After selected by antibi-
otics (600 μg/ml G418 and 1 μg/ml puromycin) and ring
cloning, the two best LNCaP clones with doxycycline
(Dox)-inducible HOXB13 were established. As shown in
Figure 3A, HOXB13 was demonstrated by Western blot
analysis in HOXB13-inducible LNCaP cells, named S2
and S4, in addition to Tet-on control cells. FLAG-tagged
HOXB13 was gradually increased by Dox in a dose-
responsive manner (50, 100, 200 nM) while the level of
endogenous HOXB13 expression was not significantly
altered by Dox. To maintain the overexpressed HOXB13
at physiological levels, the concentration of Dox required
to induce recombinant HOXB13, to the level of normal
prostate, was determined. LNCaP cells express only 10%
of HOXB13 compared to the normal prostate [15]. Densi-
tometric quantitation of FLAG-HOXB13 demonstrated
that the FLAG-HOXB13 was induced ten-fold at concen-
trations of 100 nM Dox (Figure 3B). The Dox concentra-
tion was maintained at 100 nM for further analyses.
Suppression of HOXB13 in the LNCaP cells was achieved
using a retroviral vector system. As shown in Figure 3C,
several stable transfectants were selected. These included
1-3 and 4-1 in addition to cells transfected with scram-
bled DNA. Clone 4-1S was not expandable. Next, to vali-
date whether the established clones retained known
biochemical properties, a reporter transcription assay
was performed to determine the AR repressive function
of HOXB13. HOXB13 was previously shown to strongly
repress androgen-stimulated AR activity [15]. HOXB13-
inducible cells (S4) under the influence of Dox showed
dramatic inhibition of ARE4, a synthetic promoter con-
taining four copies of androgen response elements, in a
dose responsive manner (Figure 3D). S2 cells showed the
same phenomenon (data not shown). Tet-on control cells
did not alter the androgen-stimulated AR activity by the
addition of Dox. At the same time HOXB13-suppressed
cells showed dramatic promotion of androgen-stimulated
AR activity (Figure 3E).
HOXB13 promotes androgen-independent prostate cancer 
cell growth
To monitor the in vitro cell growth of the HOXB13-
manipulated cells, a MTT assay was performed. In the
presence of the synthetic androgen (R1881) at a final con-
centration of 1nM, induction of HOXB13 by Dox drove
the S4 cells to growth inhibition as previously observed
(Figure 4A). On the other hand, in the absence of andro-
gen, induction of HOXB13 conferred a positive growth
signal on the S4 cells (Figure 4B). Addition of Dox did not
affect cell growth of the Tet-on cells in both circum-
stances (Figure 4C-D). Growth assays in HOXB13-sup-
pressed LNCaP cells were also studied; they showed that
inhibition of HOXB13 expression promoted cell growth
in the presence of androgen (Figure 4E) and inhibited cell
growth in the absence of androgen (Figure 4F). In both
circumstances, repeated-measures ANOVA revealed
very significant interaction effect between groups and
days (p < 0.0001). This phenomenon explains why
HOXB13 is overexpressed in androgen-refractory tumors
and also suggests that HOXB13 is involved in PCa cell
proliferation in both the androgen dependent and inde-
pendent environment.
HOXB13 inhibits expression of p21waf in the absence of 
androgen
Previously, we demonstrated that overexpression of
HOXB13 caused G1 cell cycle arrest in AR-negative and
HOXB13-deficient PC3 PCa cells [17]. HOXB13-induced
cell cycle arrest appears to be due to the reduction of
cyclin D1 and c-myc, which are targets of β-catenin/TCF
signaling. However, HOXB13's effect on TCF target genes
is minimal in AR-positive and HOXB13-retained
CWR22RV PCa cells. In order to verify whether there are
a n y  a l t e r e d  p r o t e i n s  i n v o l v e d  i n  t h e  G 1  c e l l  c y c l e  b y
HOXB13, HOXB13-inducible LNCaP cells (S4) were
grown in charcoal dextran-treated (CDT)-FBS for 3 days
in the absence of androgen. These cells were then treated
with 100nM Dox for 48 hours and whole cell lysates were
analyzed by Western blot. As shown in Figure 5A,
HOXB13 dramatically inhibited expression of the p21waf
protein whereas HOXB13 did not affect expression of
other cell cycle inhibitors, cyclins, and cdks. At the same
time, HOXB13 did not alter the expression of down-
stream effectors of the p21waf  protein, including RB-
related pocket proteins and E2F transcription factors.
E2F1-2 is not shown in the figures due to the poor anti-
body reactivity. Next, the p21 promoter-derived
luciferase assay was used to determine whether HOXB13
inhibits p21waf  at the transcriptional level. Figure 5B
shows that HOXB13 decreased p21 promoter activity
down to 15%, suggesting that HOXB13 inhibited tran-
scription of p21waf. Repression of p21waf was unique to
HOXB13 since other HOX-13 paralogs, generously
expressed in the prostate and possessing similar nucle-
otide sequences, did not suppress p21waf transcription. To
determine whether HOXB13-induced repression of
p21waf could activate the E2F1 response, the E2F1 pro-
moter based luciferase assay was performed in the
LNCaP cells. E2F1 is known to activate its own promoter
by direct binding [18]. HOXB13 dramatically promoted
the E2F1-mediated response (Figure 5C) and additional
E2F1 showed synergistic effects (Figure 5D, two-wayKim et al. Molecular Cancer 2010, 9:124
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Figure 3 Construction of HOXB13-manipulated LNCaP prostate cancer cells: A, HOXB13 was induced by doxycycline in S2 and S4 cells compared 
to no expression in the Tet-on control cells. B, Recombinant HOXB13 in S4 the LNCaP cells was quantitated by densitometry. The endogenous HOXB13 
level was arbitrarily set as one fold. C, Western blot analysis showed clones of HOXB13-suppressed LNCaP cells in addition to scrambled DNA-trans-
fected LNCaP. D-E, By the reporter transcription assay, the effect on androgen-stimulated AR activity was tested in the Tet-on and S4 cells and HOXB13-
suppressed clones. Cells were transiently transfected with 100 ng of pGL-ARE4-Luc and 2 ng of ranilla with or without 10 nM R1881. When needed, 
doxycycline was added with R1881 to induce HOXB13. Luciferase assays were performed 48 h post-transfection. Values indicate fold induction (RLU 
with androgen/RLU without androgen). Each bar represents the mean ± S.D.
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Figure 4 Effect of HOXB13 on androgen-independent prostate cancer cell growth: S4 and Tet-on cells were grown under androgen-rich con-
ditions (A, C) or androgen-deprived conditions (B, D) for up to 6 days in 100 nM doxycycline. HOXB13-suppressed cells (1-3 and 4-1) with scrambled 
control cells were also grown under similar conditions (E, F). The cells were stained with MTT reagent and measured at an optical density at 570 nm. 
The * in the diagram, determined by a two-tailed Student's t test, corresponds to the difference between the two groups (p < 0.05). In E and F, repeat-
ed-measures ANOVA revealed very significant interaction effect between groups and days (p < 0.0001).
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Figure 5 Effect of HOXB13 on the p21-RB-E2F signaling pathway: A, S4 cells were grown under hormone-deprived conditions for 3 days and in-
duced for HOXB13 with 100nM doxycycline. Extracted lysates were evaluated for Western blot analysis. LNCaP cells were grown under hormone-de-
prived condition for 3 days. B, Cells were transfected with p21-luc and pFLAG-HOXB13, pCDNA-HOXA13, or pCMV-HOXD13. C, Cells were transfected 
with pE2F1-luc and pFLAG-HOXB13. D, Cells were transfected with pE2F1-luc, pFLAG-HOXB13, and pCDNA-E2F1. Corresponding control vectors were 
used to match each DNA. After 48 hours, the cells were evaluated by luciferase assays. Each bar represents the mean ± S.D.
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ANOVA: F = 12.44, p < 0.01). These results suggest that
HOXB13 is involved in the activation of the oncogenic
E2F signal by downregulation of p21waf expression.
Promotion of the E2F signal by HOXB13 was mainly due to 
p21waf repression
Since HOXB13's effect on E2F did not necessarily come
from the regulation of the expression of p21waf, we tested
whether HOXB13 affects E2F response elements by way
of p21waf. First, we tested whether HOXB13's effect on
the E2F1 promoter was mediated through the E2F1 bind-
ing sites. By using three copies of simple E2F1 response
elements, HOXB13 and E2F1also showed additive effects
of the E2F1 response (Figure 6A), suggesting that E2F1
promotion by HOXB13 was mediated by the E2F1
response elements. Next, we studied HCT116 colon can-
cer cells with either wild type or deleted p21waf. Both cells
were transfected with pE2F1-luc and HOXB13. While
HCT116 (p21+/+) showed a dramatic increase in E2F
activity, in a dose responsive manner (up to 14 fold
increase), HCT116 (p21-/-) cells showed minimal pro-
moting effects (up to 4 fold increase) (Figure 6B). In addi-
tion, increase of p21 gradually decreased the E2F activity
stimulated by HOXB13 in a dose responsive manner in
the HCT116 (p21+/+) cells (Figure 6C). At maximum
expression of p21, however, the activity did not com-
pletely return to basal levels. These results suggest that
there is a minor p21-independent activation of E2F1 by
HOXB13. To verify the alteration of the E2F1 target genes
by HOXB13, Western blot and RT-PCR analyses were
performed (Figure 6D). HOXB13 up-regulated expres-
sion of the p107 pocket protein, which is a target of E2F-
mediated transactivation [19]. Since E2F1 protein expres-
sion is known to be barely detectable in cells grown under
hormone-deprived conditions [20], RT-PCR analysis
showed that HOXB13 stimulated expression of E2F1.
These results suggest that HOXB13's promoting effect on
E2F signaling mainly comes from a p21-dependent path-
way.
Discussion
HOXB13 is a highly specific prostate homeobox protein
and is involved in the formation of this hormone-domi-
nant organ [5,7,8,15]. Functionally, Hoxb13 loss-of-func-
tion mice show swollen prostate glands [8]. Involvement
of HOXB13 during carcinogenesis of human tissues has
been reported by many groups [21-24]. Many reports
have published findings supporting a link between and
several solid tumors, including breast cancer, cervical
cancer, ovarian cancer, and skin cancers [16,24-29]. In
breast cancer, HOXB13 was found to be overexpressed in
hormone-refractory tumors compared to hormone-
responsive tumors, further suggesting that HOXB13
might be a useful prognostic marker for hormone-refrac-
tory breast cancers [26]. In addition, the forced expres-
sion of HOXB13 promoted the growth of MCF10A
estrogen receptor (ER)-negative breast cells along with
increased migration and invasion. In this report, we have
demonstrated that HOXB13 was also overexpressed in
hormone-refractory prostate tumors; its expression pro-
vided a positive growth signal in the absence of androgen.
Our previous reports showed no expression of HOXB13
in only PC3 and DU145 cells [15]. While these cells are
described as androgen-independent prostate cancer cells,
they are generally considered as 'non-prostate-like cancer
cells' mainly due the deficiency of androgen receptors
(AR). In addition, there was positive correlation between
HOXB13 and AR with consequent functional counterac-
tion between these two proteins, suggesting that
HOXB13 functions as a PCa cell growth suppressor in the
presence of androgen [15]. HOXB13 antagonizes the
function of the androgen-stimulated AR signal by dis-
rupting coactivator formation. Although the prognostic
value of the HOXB13, for the progression of PCa,
requires further study, it is surprising that the function of
HOXB13 is paradoxically opposite, depending on the sta-
tus of androgen. In fact, tumor suppressor NKX3.1
homeodomain protein is overexpressed in metastatic
prostate cancer [30]. In ovarian cancer, HOXB13 pro-
motes cancer cell proliferation and progression [28].
Taken together, the balance between HOXB13 and the
AR is important for the modulation of growth in PCa
cells. In other words, HOXB13 expression must be dereg-
ulated for the survival of androgen-independent tumors
while its expression is highly maintained in tumors with
high androgen responsiveness.
Some HOX proteins are involved in the progression of
PCa. Both HOXC6 and HOXC8 have been shown to be
overexpressed in more advanced metastatic and recur-
rent PCa [31,32]. Despite the high expression of HOXB13
in the normal prostate, alteration of HOXB13 expression
during the transformation process remains controversial.
Some studies suggest overexpression of HOXB13 in pros-
tate tumors [13,33], while others reported no such change
[15,34]. Using total RNA we did not observe a differential
expression of HOXB13 between the benign and malig-
nant tumors; this was likely due to the multifocal nature
of PCa [15]. In addition, immunohistochemical staining
did not demonstrate alteration of HOXB13 during the
tumorigenic process (unpublished data). Suppression or
down-regulation of HOXB13 has been observed in other
tumors, including colorectal cancer and skin tumors [22-
24,35], although the level of HOXB13 protein was not
detectable in normal skin. It is believed that the expres-
sion pattern and role of HOXB13 can be significantly dif-
ferent in breast cancers and PCa based on the following
observations: 1) Breast tissues are HOXB13-negative as
reported by many groups [6,14-16]. Accordingly, all cul-Kim et al. Molecular Cancer 2010, 9:124
http://www.molecular-cancer.com/content/9/1/124
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tured breast cancer cells, including several MCF7,
MCF10a, T47D, and MDA 231, showed no expression or
only minimally expressed HOXB13 [16,36]. 2) While
HOXB13 and estrogen signals can be mutually regulated
in breast cancer [21], there is no mutual regulation of
HOXB13 and the androgen receptor in PCa [15]. 3)
HOXB13 promotes growth of MCF10A cells, ER-negative
normal breast cells [26] but HOXB13 inhibits AR-nega-
tive PC3 PCa cells by regulating β-catenin/TCF signals
[17]. Therefore, the role of HOXB13 is variable depend-
ing on the cell type itself and the cell environment.
This study demonstrated that HOXB13 was overex-
pressed in androgen-refractory prostate tumors and was
involved in providing a positive growth signal to PCa cells
Figure 6 Effect of HOXB13 on p21-dependent E2F1-mediated transactivation: A, LNCaP cells were grown under hormone-deprived conditions 
for 3 days and transfected with pE2F1(3X)-luc, pFLAG-HOXB13, and pCDNA-E2F1. B, Both HCT116 (p21+/+) and HCT116 (p21-/-) cells were transfected 
with pE2F1-luc and an increased amount of pFLAG-HOXB13. C, HCT116 (p21+/+) cells were transfected with pE2F1-luc, pFLAG-HOXB13, and an in-
creased amount of pFLAG-p21. Corresponding control vectors were used to match each DNA. After 48 hours, the cells were evaluated for luciferase 
assays. Each bar represents the mean ± S.D. D, S4 cells were treated with Dox to induce HOXB13 followed by Western blot and RT-PCR analyses.
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in the absence of androgen. In fact, Hoxb13 regulatory
elements have been shown to successfully mediate trans-
gene expression in castrated transgenic mice, demon-
strating that HOXB13 expression is not affected by
androgen or hormone blockage therapy [37]. Hormone-
independent growth promotion by HOXB13 appears to
be mainly due to the inhibition of tumor suppressor
p21waf expression and the consequent release of the E2F1
transcription factor from the RB family pocket proteins.
More available E2F1 activates its target gene transcrip-
tion, generally causing heperproliferation of cells [38,39].
The RB/E2F pathway is deregulated in many cancers
[40,41] and overexpression of E2F1 also prevents andro-
gen-withdrawal-mediated growth arrest and high levels
of E2F1 expression represses neuroendocrine differentia-
tion of androgen independent cells [20]. Taken together, a
model of HOXB13's role in androgen-independent sur-
vival of PCa cells is shown in Figure 7. With low or no
androgen influence, HOXB13 inhibits p21 expression to
promote activity of CDK2. Consequent phosphorylation
of the RB protein by CDK2 releases the E2F1 transcrip-
tion factor to drive expression of its target gene, such as
c-myc, p107, and E2Fs. These oncogenes provide positive
growth signals to the PCa cells for survival in a harsh
environment such as one without androgen hormones.
The role of HOXB13 in androgen independent survival
signaling pathways, such as interlukin-6 and protein
kinase A-dependent CREB pathways, requires further
study. In addition, the detailed mechanism of the action
of HOXB13 on the p21 promoter requires further clarifi-
cation to fully understand HOXB13's role in the p21-RB-
E2F signaling pathway.
Conclusions
Lack of information on androgen-independent progres-
sion of prostate cancer cells makes clinicians to difficult
to properly treat patients with hormone-refractory can-
cers. This study demonstrated that HOXB13 homeodo-
main protein is overexpressed in hormone-refractory
prostate cancer. Underlying mechanism on HOXB13-
mediated growth stimulation seems to come from the
specific inhibition of p21 followed by subsequent activa-
tion of RB/E2F1 signaling. This study presents a novel
pathway to better understand androgen-independent
survival of prostate cancer cells and suggests that upregu-
lation of HOXB13 confers additive growth advantage to
p r o s t a t e  c a n c e r  c e l l s  i n  n o  o r  l o w  a n d r o g e n  s t a t u s  b y
alteration of p21-mediated E2F signal, a decisive growth
regulator.
Methods
Patient cohort
Paraffin-embedded human primary PCas were obtained
from patients after they provided informed consent to
participate in this study at Chonnam National University
Hospital between 1997 and 2005. Specimens from 56
patients were included; 12 had recurrent PCas with prior
hormone adjuvant therapy [See Additional file 1; Table
S1]. The treatment modalities were; orchiectomy,
luteinizing hormone-releasing hormone analogue, estro-
gen, and combined androgen blockade. The median time
from onset of the androgen ablation to androgen-inde-
pendent progression was 15.6 months (range: 7-48). Due
to the rarity of hormone-dependent tumors following
hormone ablation therapy, the hormone-dependent
tumors were acquired by radical prostatectomy while
hormone-refractory tumors were obtained by transure-
thral resection of the prostate [See Additional file 2; Table
S2]. Hormone-dependent tumors were defined as tumors
with no recurrence of a PSA >0.4ng/ml after surgery. All
cases had clinical follow-up for at least 3-years and up to
10 years. Benign prostate tissues obtained from radical
prostatectomy procedures were used to determine the
baseline expression of HOXB13.
Antisera
Anti-HOXB13 antibodies were produced against a KLH
fusion protein containing the C-terminal end of the
human HOXB13 sequence (EKKVLAAKVKNSATP) in
two New Zealand white rabbits as described by Komuves
et al [24]. The synthetic peptides did not show any
sequence homology to any known proteins searched for
using BLAST. Antisera were produced under contractual
agreement by Sigma Genosys (St. Louis, MO, USA). Anti-
bodies were positively affinity purified by affinity chro-
matography against immobilized HOXB13 synthetic
peptides.
Immunostaining
For the immunocytochemistry, cells were plated onto 2-
well chamber slides at 30% confluence. After overnight
Figure 7 Model of HOXB13-mediated regulation of E2F signaling: 
Overexpression of HOXB13 in androgen-refractory prostate tumors in-
hibits the expression of the p21 waf tumor suppressor and subsequent-
ly activates cyclin dependent kinase 2 (CDK2) activities. 
Hyperphosphorylated RB releases E2F transcription factor, which 
drives the genes involved in cell proliferation, and results in increased 
cell survivability in the absence of hormone.Kim et al. Molecular Cancer 2010, 9:124
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incubation, the cells were fixed with methanol/acetone
solution for 15 minutes. Then, the cells were treated with
0.2% Triton X100 in PBS for 10 minutes. Anti-HOXB13
antibodies in 2% BSA/PBS were added to the slides for 1
hour. After washing, the slides were incubated with don-
key anti-rabbit IgG (Fab fragment) conjugated to peroxi-
dase (Jackson Laboratories). Colorimetric signals were
detected using diaminobenzidine (DAB). Sections were
counterstained with hematoxylin for microscopic evalua-
tion. Immunohistochemistry was performed as described
previously [24]. Tissues were deparaffinized followed by
microwave antigen retrieval in citrate buffer. Endogenous
peroxidase activity was destroyed by the treating tissue
sections with 3% H2O2. After nonspecific reactivity was
sequentially blocked by an Avidin-Biotin Blocking
Reagent and 10% normal goat serum, the tissues were
incubated with anti-HOXB13 antibodies and then with
donkey anti-rabbit IgG (Fab fragment) conjugated to per-
oxidase (Jackson Laboratories). Colorimetric signals were
detected using DAB. Sections were counterstained with
hematoxylin for microscopic evaluation. Anti-androgen
receptor antibodies (Upstate) were used to confirm tissue
integrity. For the negative control slide, non-immune rab-
bit IgG was used. The immunostained slides were evalu-
ated by two different investigators, including a
pathologist, blinded to the patient's clinical features. The
intensity of the HOXB13 staining was classified into one
of four grades (0, absent; 1, weak; 2, intermediate; and 3,
strong). Tumors with less than 5% HOXB13 expression
were considered negative regardless of the intensity
described [42]. This approach has been previously deter-
mined to be reliable and reproducible by several groups
[43-45].
Cell culture
Human PCa cell lines, LNCaP, PC3, and DU145, were
routinely cultured in RPMI media (Invitrogen) supple-
mented with 5% FBS at 37°C in an atmosphere containing
5% CO2. MDA PCa 2b cells were grown in BRFF-HPC1
medium (Athena Environmental Sciences, Inc., Balti-
more, MD, USA) with 20% FBS. Wild type HCT116
(p21+/+) and HCT116 (p21-/-) were kindly provided by
Dr. Bert Vogelstein and have been well described previ-
ously [46]. All cultures were fed with fresh medium every
3-4 days.
Plasmids and reagents
The pFLAG-HOXB13 and pGL-ARE4-Luc have been
previously described [17]. The p21-luc, incorporating a
2.4 kb genomic fragment from the p21 promoter was
kindly provided by Dr. Vogelstein. The pFLAG-p21 vec-
tor was constructed by PCR cloning. The pCMV-E2F1
was kindly provided by Dr. Hong-Wu Chen (UC Davis).
The pE2F1-luc was provided by Dr. Chihuei Wang (Kaoh-
siung Medical University, Taiwan). pCMV-Hoxa13 and
pCDNA-Hoxd13 were constructed from pMiw-Hoxa13
and pBK-Hoxd13, respectively, both of which were of
mouse origin and provided by Dr. Atsushi Kuroiwa
(Nagoya University, Japan). Antibodies to p16, p18, p21,
p27, CDK2, CDK4, CDK6, CDK8, Cyclin D1, D2, D3, E,
p107, RB, p130, E2F1-5, DP1-2, the androgen receptor
and β-actin were from Santa Cruz Biotechnology. Anti-
FLAG M5 antibodies and doxycycline were from Sigma.
pTet-on, pTRE-luc, and pTRE-puro were from BD Biosci-
ences. Synthetic testosterone, R1881, was from NEN Life
Science (Boston, MA, USA) and used at a final concen-
tration of 10 nM. Both charcoal dextran-treated (CDT)
FBS and tetracycline-free FBS were from Invitrogen.
Transient transfections
Approximately 1 × 105 cells were plated in a 24-well plate
16 hours before transfection. To determine the hormone
effects, cells were grown under 5% charcoal dextran-
treated (CDT) FBS for three days before the transfection.
Transfections were carried out using Lipofectamine 2000
(Invitrogen) with 0.1 μg of reporter, 0.1 μg of test plasmid,
and 2 ng of ranilla as described by the manufacturer's
protocol. Six hours after transfection, the cells were
washed and fed with medium containing 5% CDT-FBS. If
needed, the cells were treated with either 10 nM R1881
synthetic androgen or ethanol. After 36 hours, the cells
were washed with PBS, lysed with 100 μl of passive lysis
buffer, and assayed for luciferase activity as relative light
units (RLU) using a dual luciferase assay system (Pro-
mega). Transfection experiments were performed in trip-
licate and the results are reported as mean ± S.D.
Stable transfections
Using the Tet-On system (BD Biosciences), the LNCaP
PCa cells were transfected with Tet-on and a single clone
was obtained by ring cloning and G418 selection (600 μg/
ml; Invitrogen). Inducibility of the resulting clones was
tested by transient transfection using pTRE-luc in the
presence of doxycycline (Sigma). A second transfection
was performed with pTRE-puro expressing FLAG-tagged
HOXB13, followed by ring cloning and puromycin selec-
tion (1 μg/ml). The two best clones in terms of growing
ability and protein inducibility were selected, namely S2
and S4. The Tet-on transfected cells were used as control
cells. To suppress the HOXB13 in the LNCaP cells, short
hairpin oligonucleotides were generated from either the
5' or 3' end of the HOXB13 [17]. The DNAs were ligated
into the H1 RNA gene promoter-based vector, pSU-
PER.retro (DNA Engine, Seattle, WA, USA). The result-
ing vector was infected into PA316 packaging cells to
produce retroviral supernatants. After infection of the
LNCaP cells, viral plaques were isolated by a ring clone
and selected by 1 μg/ml puromycin.Kim et al. Molecular Cancer 2010, 9:124
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Western Blotting Assay
Cells were grown to 50% confluence in P60 culture dishes
containing 5% FBS-RPMI media. If necessary, the cells
were grown in RPMI media containing either 5% tet-free
FBS or CDT-FBS. The cells were then lysed in protein
extraction buffer (1x TBS, 1% NP-40, 0.5% sodium deoxy-
cholate, 0.1% SDS and protease inhibitors) followed by
needle sonication to break up the ribonucleosome.
Twenty μg of total cell lysates were loaded onto 10% Bis-
Tris gel (Invitrogen) and separated using a Biorad elec-
troporation system. After the proteins were transferred to
a PVDF membrane, the primary antibodies were applied,
followed by incubation with horse peroxidase-conjugated
secondary antibodies. The blots were developed using the
ECL detection system (Pierce).
RT-PCR
RNA extraction from the cells was performed as previ-
ously described [47]. RT-PCR was performed to verify the
expression of HOXB13, E2F1, and β-actin. The primer
sequences for each gene were as follows: HOXB13fw, 5'-
ccccactgagtttgccttctatc-3'; HOXB13rv, 5'-gcctcttgtccttg-
gtgatgaac-3'; E2F1fw, 5'-aggccgccatccaggaaaag-3'; E2F1rv,
5'-ggatgccctcaacgacgttg -3'; β-actinfw, 5'-gcaccacaccttcta-
caatgagc-3'; β-actinrv, 5'-tagcacagcctggatagcaacg-3'.
Growth Assays
The MTT in vitro proliferation assay was performed as
previously described [17]. Briefly, the cells were grown in
RPMI media containing 5% CDT-FBS for three days and
then plated on 24-well plates at 30% confluence. The next
day, if needed, the cells were treated with 100nM doxycy-
cline and/or 1nM R1881 and grown for up to 7 days.
Then, the cells were stained with 100 μl of 5 mg/ml MTT
solution and incubated for 2 hours at 37°C. The reaction
was stopped by adding 400 μl of extraction buffer (50%
formamide and 10% SDS, pH 4.7). After overnight incu-
bation at 37°C, the absorbance at 570 nm was measured
using a microplate reader with SOFTmax PRO software
(Molecular Devices, Sunnyvale, CA, USA). Densitomet-
ric values were analyzed with the Student's t test, using
GraphPad Prism software (San Diego, CA, USA).
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